ArticleESMO gastrointestinal oncology2026
The Danish randomized trial of trifluridine-tipiracil and bevacizumab in metastatic colorectal cancer: final survival and
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In 2020, we published the first randomized trial demonstrating the efficacy of trifluridine-tipiracil (FTD-TPI) with bevacizumab compared with FTD-TPI monotherapy in chemorefractory metastatic colorectal cancer. This study aims to: (i) analyze final survival data, (ii) perform Materials and methods: The Kaplan-Meier method and Cox proportional hazards models were used to analyze final survival data for all 93 patients included in the trial. CIN was modeled as a time-varying covariate. Results: Progression-free survival was 4.6 months [95% confidence interval (CI) 3.7-6.5] with FTD-TPI plus bevacizumab versus 2.4 months (95% CI 1.8-3.6) with FTD-TPI; hazard ratio (HR) 0.47 (95% CI 0.31-0.73). Overall survival was 10.0 months (95% CI 8.1-12.7) with FTD-TPI plus bevacizumab versus 6.0 months (95% CI 5.5-7.9) with FTD-TPI; HR 0.55 (95% CI 0.36-0.84). CIN was associated with reduced hazard of progression; HR 0.32 (95% CI 0.15-0.70) for FTD-TPI and HR 0.22 (95% CI 0.10-0.52) for FTD-TPI plus bevacizumab. CIN was also associated with reduced hazard of death: HR 0.62 (95% CI 0.39-0.97) for FTD-TPI and HR 0.64 (95% CI 0.35-1.17) for FTD-TPI plus bevacizumab. Patients receiving FTD-TPI plus bevacizumab had longer time to PS worsening to ≥2: HR 0.39 (95% CI 0.25-0.61). Conclusions: Our findings support the superiority of FTD-TPI plus bevacizumab over FTD-TPI in prolonging survival and maintaining PS. CIN was associated with improved survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.